Literature DB >> 19120365

Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.

Klio Konstantinou1, Kouhei Yamamoto, Fumiaki Ishibashi, Yuiko Mizoguchi, Morito Kurata, Yasunori Nakagawa, Kenshi Suzuki, Motoji Sawabe, Masatsugu Ohta, Shigesaburo Miyakoshi, James T Crawley, Masanobu Kitagawa.   

Abstract

Angioimmunoblastic T-cell lymphoma (AILT) is a malignant disease of peripheral T-cell origin that is characterized by a prominent proliferation of high endothelial venules in the lymph node. To investigate angiogenic mechanisms in AILT we measured the angiogenic mediator gene expression levels in the lymph nodes of 54 non-Hodgkin lymphoma patients, by immunostaining and quantitative reverse transcription polymerase chain reaction. Angiogenic mediators angiopoietin (Ang) 1 (ANGPT1), Ang2 (ANGPT2) and their receptor, Tie2 (TEK), vascular endothelial growth factor (VEGF; VEGFA) and its receptor, VEGFR2 (KDR), and hepatocyte growth factor (HGF) and its receptor, c-Met (MET) were all more highly expressed in AILT lymph nodes (16 cases) than in B-cell lymphomas (24 cases). Moreover, significantly higher Ang1 and Tie2 expression was detected in AILT cases with CD10-positive neoplastic T-cells by comparison with unspecified peripheral T-cell lymphoma (14 cases). Immunostaining confirmed the expression of Ang1 and VEGF by both neoplastic T-cells and follicular dendritic cells. These results suggest that the angiopoietin system may play an important role in the development of high vascularity in AILT lymph nodes. Consequently, as neoplastic T-cells and follicular dendritic cells are both increased in AILT and may represent an important source of angiogenic mediators, targeting these cells with anti-angiogenic strategies might represent a novel therapy for AILT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120365     DOI: 10.1111/j.1365-2141.2008.07534.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

2.  Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Authors:  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-21

3.  BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.

Authors:  Philippe Ratajczak; Christophe Leboeuf; Li Wang; Josette Brière; Irmine Loisel-Ferreira; Catherine Thiéblemont; Wei-Li Zhao; Anne Janin
Journal:  Mod Pathol       Date:  2012-02-10       Impact factor: 7.842

4.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells.

Authors:  Florencia Cayrol; María Celeste Díaz Flaqué; Tharu Fernando; Shao Ning Yang; Helena Andrea Sterle; Marcela Bolontrade; Mariana Amorós; Blanca Isse; Ricardo Norberto Farías; Haelee Ahn; Ye F Tian; Fabrizio Tabbò; Ankur Singh; Giorgio Inghirami; Leandro Cerchietti; Graciela Alicia Cremaschi
Journal:  Blood       Date:  2014-12-08       Impact factor: 22.113

5.  Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations.

Authors:  Luis Alberto de Pádua Covas Lage; Tamara Carvalho Dos Santos Cabral; Renata de Oliveira Costa; Marianne de Castro Gonçalves; Debora Levy; Maria Cláudia Nogueira Zerbini; Juliana Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-07

6.  Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.

Authors:  Qunling Zhang; Junning Cao; Kai Xue; Xiaojian Liu; Dongmei Ji; Ye Guo; Xiaonan Hong
Journal:  Onco Targets Ther       Date:  2016-12-22       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.